SAN
DIEGO, May 19, 2022 /PRNewswire/ -- Inhibrx, Inc.
(Nasdaq: INBX), a biotechnology company with four clinical programs
in development and an emerging pre-clinical pipeline, announced
today that it will be presenting details on the trial design for
the INBRX-109 Phase 2 potentially registration-enabling trial in
conventional chondrosarcoma at the 2022 American Society of
Clinical Oncology ("ASCO") Annual Meeting to be held June 3rd through June 7th, 2022 in Chicago, Illinois.
Details on the poster presentation are shared below:
Title: A randomized, placebo-controlled phase 2 trial
of INBRX-109 in unresectable or metastatic conventional
chondrosarcoma
Track/Session: Sarcoma
Poster
number:486a
Presenter: Sant P.
Chawla, MD
Date & Time: Sunday, June 5, 2022 from 9 a.m. to 11 a.m. CST
Location: Exhibit
Hall A
The poster will be available on-demand on the ASCO website for
attendees beginning at 9:00 AM CST on
Friday, June 3, 2022. Upon release at ASCO, the scientific
poster will be accessible through Inhibrx's website at
https://inhibrx.investorroom.com/events-and-presentations.
About Chondrosarcoma
Chondrosarcoma is an orphan bone cancer with approximately 2,800
new patients diagnosed annually in the
United States and the European Union. There are currently no
systemic therapies approved for the treatment of
chondrosarcoma.
About INBRX-109
INBRX-109 is a precision-engineered, tetravalent death receptor
5 (DR5) agonist antibody designed to exploit the tumor-biased cell
death induced by DR5 signaling.
In January 2021, the FDA granted
Fast Track designation to INBRX-109 for the treatment of patients
with unresectable or metastatic conventional chondrosarcoma.
Further, in December 2021, FDA
granted Orphan Drug Designation to INBRX-109 for this
indication.
In November 2021, Inhibrx provided
updated results from its ongoing Phase 1 clinical trial evaluating
the efficacy and safety of INBRX-109 in patients with conventional
chondrosarcoma. Preliminary disease control was observed in 16 of
the 18 evaluable patients (89%) measured by RECISTv1.1, with two of
the 18 achieving partial responses (11%). Based on preliminary
results of the ongoing Phase 1 trial, the median progression-free
survival (PFS) is 7.4 months, and the median overall survival has
not been reached. Three patients have exceeded 61 weeks on
treatment with INBRX-109, with 77 weeks being the longest duration
of stable disease observed to date.
In June 2021, Inhibrx initiated a
randomized, blinded, placebo-controlled, potentially
registration-enabling Phase 2 trial of INBRX-109 in conventional
chondrosarcoma. The trial will be conducted at approximately 51
sites within eight countries, with 30 of those sites in
the United States.
About Inhibrx, Inc.
Inhibrx is a clinical-stage biotechnology company focused on
developing a broad pipeline of novel biologic therapeutic
candidates in oncology and orphan diseases. Inhibrx utilizes
diverse methods of protein engineering to address the specific
requirements of complex target and disease biology, including its
proprietary sdAb platform. Inhibrx has collaborations with 2seventy
bio (formerly bluebird bio), Bristol-Myers Squibb and Chiesi. For
more information, please visit www.inhibrx.com.
Investor and Media Contact:
Kelly Deck
CFO
kelly@inhibrx.com
858-795-4260
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-details-of-presentation-at-2022-asco-annual-meeting-301551620.html
SOURCE Inhibrx, Inc.